What is Seed?
Headquartered in Venice, California, Seed operates at the intersection of biotechnology and consumer packaged goods. The company specializes in the research, manufacturing, and direct-to-consumer sale of probiotic supplements designed to support systemic human health. Unlike traditional supplement providers, Seed emphasizes a rigorous, science-first methodology, ensuring that its products are backed by clinical research and sustainable manufacturing practices. This commitment to quality has allowed the firm to carve out a distinct niche in the competitive wellness industry, effectively bridging the gap between pharmaceutical-grade research and accessible consumer health solutions.
How much funding has Seed raised?
Seed has raised a total of $40M across 1 funding round:
Series A
$40M
Series A (2021): $40M with participation from 8VC, Artis Ventures Management Iii, Founders Fund, The Craftory, and GISEV
Key Investors in Seed
8VC
8VC is a leading technology investment firm that focuses on smart enterprise platforms across industries including healthcare and Bio-IT, managing $3.6 billion in committed capital.
Artis Ventures Management Iii
Artis Ventures is a dedicated venture capital fund focused on Tech Bio and Health, investing in data-driven life sciences companies that aim to enhance human health and wellness.
Founders Fund
Founders Fund invests in the world's most important and valuable companies across all geographies and stages, known for its founder-friendly investment strategy.
What's next for Seed?
Looking ahead, the infusion of capital will likely be directed toward scaling operational infrastructure and accelerating research and development initiatives. As the company transitions into a more mature enterprise-level lifecycle stage, the focus will shift toward optimizing supply chain logistics and expanding its product portfolio to address a wider array of health markers. Strategic partnerships with institutional investors will provide the necessary guidance to navigate the complexities of the global health market, ensuring that Seed remains at the forefront of microbiome innovation. The company is poised to leverage its current momentum to set new standards for transparency and efficacy in the probiotic sector, potentially exploring new international markets and advanced therapeutic applications for its proprietary bacterial strains.
See full Seed company page
